ITI214

• CAT Number: I002147
• CAS Number: 1642303-38-5
• Molecular Formula: C29H29FN7O5P
• Molecular Weight: 605.567
• Purity: ≥95%
• Target: Phosphodiesterase (PDE)
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: 58 pM (Ki)
• InChI: InChI=1S/C29H26FN7O.H3O4P/c1-35-28(38)25-26(31-20-7-3-2-4-8-20)36(34-27(25)37-23-11-5-10-22(23)33-29(35)37)17-18-13-15-19(16-14-18)21-9-6-12-24(30)32-21;1-5(2,3)4/h2-4,6-9,12-16,22-23,31H,5,10-11,17H2,1H3;(H3,1,2,3,4)/t22-,23+;/m1./s1
• InChIKey: ZPIAAFIYOPWWJL-RFPXDPOKSA-N
• SMILES: CN1C(=O)C2=C(N(N=C2N3C1=NC4C3CCC4)CC5=CC=C(C=C5)C6=NC(=CC=C6)F)NC7=CC=CC=C7.OP(=O)(O)O

ITI214 (Cat.No:I002147) is a novel small molecule drug being investigated for its potential therapeutic applications. It acts as a potent and selective inhibitor of phosphodiesterase 1 (PDE1), an enzyme involved in regulating intracellular levels of cyclic nucleotides. By inhibiting PDE1, ITI214 may modulate cellular signaling pathways and have potential therapeutic effects in various disease conditions. Clinical trials are being conducted to explore its efficacy and safety profile.

Reference

[1]. Li P, et al. Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases. J Med Chem. 2016 Feb 11;59(3):1149-64.
[2]. Lawrence Wennogle. Novel uses. From PCT Int. Appl. (2014), WO 2014145617 A2 20140918.
[3]. Peng Li , et al. Salt crystals. From PCT Int. Appl. (2013), WO 2013192556 A2 20131227.
[4]. Allen A. Fienberg, et al. Organic compounds. From PCT Int. Appl. (2010), WO 2010132127 A1 20101118.